10-year follow-up of intensive glucose control in type 2 diabetes
about
Critical illness-induced dysglycaemia: diabetes and beyondFirst human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitusAlpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trialsComparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinationsManagement of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Use of metformin in the setting of mild-to-moderate renal insufficiencyESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryRepurposing metformin: an old drug with new tricks in its binding pocketsSulphonylurea monotherapy for patients with type 2 diabetes mellitusTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusPramlintide for diabetes mellitusInsulin and glucose-lowering agents for treating people with diabetes and chronic kidney diseaseSulphonylurea monotherapy for patients with type 2 diabetes mellitusGlucose lowering therapies for chronic kidney disease and kidney transplantationTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusPatient-adjusted versus health professional-adjusted insulin dosing for type 2 diabetes mellitusInsulin detemir versus insulin glargine for type 2 diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusPramlintide for diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusThe role of epigenetics in the pathology of diabetic complicationsStandards of medical care in diabetes--2012Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversionCardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?Continued efforts to translate diabetes cardiovascular outcome trials into clinical practiceMicrovasular and macrovascular complications in diabetes mellitus: Distinct or continuum?Diabetes Drugs and Cardiovascular SafetyAdvances in the treatment of type 2 diabetes: impact of dulaglutide"Inflammaging" as a Druggable Target: A Senescence-Associated Secretory Phenotype-Centered View of Type 2 DiabetesFinding Ponce de Leon's Pill: Challenges in Screening for Anti-Aging MoleculesThe EMPA-REG outcome study: critical appraisal and potential clinical implicationsDiabetes DyslipidemiaGenetics of cardiovascular and renal complications in diabetesSodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metforminThe Affordable Care Act and Diabetes Diagnosis and Care: Exploring the Potential ImpactsIncretin-Based Therapy for Prevention of Diabetic Vascular ComplicationsEarly Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular TrialsDiabetes Mellitus, Arterial Wall, and Cardiovascular Risk Assessment
P2860
Q21194913-52ADA47C-4379-4708-8E2A-43CC135C10FAQ21195757-4553B21E-FFF0-4FBF-8CA0-9C525382738AQ21285063-C49668C8-E53A-4384-8044-D725139661B7Q22241134-7B0B5DE2-6CAA-4ACF-BC43-F669D9138B81Q22241288-2BE6DBEC-614B-475C-A8C1-9E27993A3028Q22241290-7D2FFC49-03DD-4BF5-923E-37779CA9F744Q22241786-59EF3CBB-D5E7-4362-9684-72ECBF324626Q22250976-22B4DA1B-EBEC-4231-9777-6C48C7773AFDQ24186660-091D1ADB-D0B2-4251-A26F-F1828BA25973Q24186667-90130326-0862-4EBB-87DF-F255932BFDDAQ24186857-4366E0D6-7DE0-46D5-AD15-52D82F052A54Q24188192-310A5A94-88BA-471C-ADC7-09BCFFD1CA47Q24197884-5EA438DD-0979-4A70-AE9F-574ECA49647BQ24201814-ABE0AC67-928B-4E5D-AA64-077BC0250A3AQ24202505-BCF8F412-4C56-411F-B7C9-ABA1E0BAB09EQ24202547-E2581017-15B6-4F10-8CE6-B17DE90253B7Q24235596-C0704974-2871-4DCD-A157-2C9D3A24D96EQ24235718-D59F6D4E-2D46-4176-98F9-E078FC32DE27Q24236456-D7AB235D-BEA3-420B-8037-832E18696F6CQ24240172-3B62466D-79E4-456E-A42F-615C86EE92A5Q24240522-8ABCA12B-E707-4065-BE21-03E61A352114Q24241529-4F61FB00-72B8-4DD1-9A00-04358EA36EC8Q24609124-632B3BE0-FC83-4481-B749-D5E8CD82BDAAQ24632533-8CF6215D-BEA5-43E6-8BF2-07D0F1505A3EQ26740171-7871020F-3CC8-4FC1-9B43-1C1838B063F5Q26740247-DB5DE9AB-3C13-43E2-ACA9-499C495ADD98Q26741860-6C4BBFB2-8E23-4B96-8AD7-8D6CA428BB43Q26745606-ED94E190-ED20-4BEB-A10F-A662791BA572Q26746085-48BC6B89-CC62-4165-A596-2FCFAEB9E926Q26746220-0E700A42-F7FE-4C63-B937-1BB268C97D2AQ26747251-84C08CD8-AD24-4A54-BD3D-10A280B23187Q26747742-6E556279-1257-45E3-B6CC-3FEC860B0AD5Q26748742-11318F16-41C0-4A7E-B761-F672AAFB12B2Q26750905-2CE5C984-C600-415D-8F9C-55D5CD479361Q26752749-0CDB4037-C5E7-4381-8256-BEDEA4ADEB12Q26752815-51A735CB-5119-4E85-917C-B003998497DAQ26764842-164CE842-F2A4-4573-A353-E634C76BAF38Q26765470-EBEE4ECB-6C2D-4D60-A11E-91A7B86C503AQ26767164-DBDAFEF9-91DB-43AF-B152-2FE756E087B4Q26767215-2EBC955D-D450-4478-8940-0B9AFCB650E6
P2860
10-year follow-up of intensive glucose control in type 2 diabetes
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
10-year follow-up of intensive glucose control in type 2 diabetes
@ast
10-year follow-up of intensive glucose control in type 2 diabetes
@en
type
label
10-year follow-up of intensive glucose control in type 2 diabetes
@ast
10-year follow-up of intensive glucose control in type 2 diabetes
@en
prefLabel
10-year follow-up of intensive glucose control in type 2 diabetes
@ast
10-year follow-up of intensive glucose control in type 2 diabetes
@en
P50
P3181
P356
P1476
10-year follow-up of intensive glucose control in type 2 diabetes
@en
P2093
David R Matthews
H Andrew W Neil
P304
P3181
P356
10.1056/NEJMOA0806470
P407
P577
2008-09-10T00:00:00Z